EP1814563A4 - Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress - Google Patents

Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress

Info

Publication number
EP1814563A4
EP1814563A4 EP05778709A EP05778709A EP1814563A4 EP 1814563 A4 EP1814563 A4 EP 1814563A4 EP 05778709 A EP05778709 A EP 05778709A EP 05778709 A EP05778709 A EP 05778709A EP 1814563 A4 EP1814563 A4 EP 1814563A4
Authority
EP
European Patent Office
Prior art keywords
predictors
therapy
disease
response
platelet activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05778709A
Other languages
German (de)
French (fr)
Other versions
EP1814563A2 (en
Inventor
Sabrinah E Chapman-Montgomery
David Okrongly
Charaf E Ahnadi
Alan Wu
Andre Gervais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Inc
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of EP1814563A2 publication Critical patent/EP1814563A2/en
Publication of EP1814563A4 publication Critical patent/EP1814563A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP05778709A 2004-07-26 2005-07-26 Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress Withdrawn EP1814563A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59102504P 2004-07-26 2004-07-26
US60359404P 2004-08-23 2004-08-23
PCT/US2005/026496 WO2006014958A2 (en) 2004-07-26 2005-07-26 Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress

Publications (2)

Publication Number Publication Date
EP1814563A2 EP1814563A2 (en) 2007-08-08
EP1814563A4 true EP1814563A4 (en) 2008-04-16

Family

ID=35787771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05778709A Withdrawn EP1814563A4 (en) 2004-07-26 2005-07-26 Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress

Country Status (3)

Country Link
US (2) US7723064B2 (en)
EP (1) EP1814563A4 (en)
WO (1) WO2006014958A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014958A2 (en) * 2004-07-26 2006-02-09 Bayer Healthcare Llc Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress
US8021854B2 (en) * 2007-10-05 2011-09-20 Attila Mady Method of treating vascular disease
KR101808757B1 (en) * 2011-01-25 2017-12-14 주식회사 동진쎄미켐 Photocurable resin composition for imprint lithography
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US20190388548A1 (en) * 2018-06-26 2019-12-26 Tzu Chi University Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817519A (en) * 1995-12-28 1998-10-06 Bayer Corporation Automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples
US6025201A (en) * 1995-12-28 2000-02-15 Bayer Corporation Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples
AU775260B2 (en) * 1999-03-31 2004-07-29 Bayer Corporation Single channel, single dilution detection method
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
GB0027309D0 (en) * 2000-11-08 2000-12-27 Barts And The London Nat Healt Method of measuring measuring platlet activation
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CA2485722A1 (en) * 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
WO2006014958A2 (en) * 2004-07-26 2006-02-09 Bayer Healthcare Llc Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AHNADI CHARAF ET AL: "Preoperative platelet activation and C-reactive protein levels and relationship in patients with acute coronary syndrome.", BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), & 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 68b, XP009096573, ISSN: 0006-4971 *
ASHMAN NEIL ET AL: "Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients.", NEPHROLOGY, DIALYSIS, TRANSPLANTATION : OFFICIAL PUBLICATION OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION - EUROPEAN RENAL ASSOCIATION OCT 2003, vol. 18, no. 10, October 2003 (2003-10-01), pages 2088 - 2096, XP002470689, ISSN: 0931-0509 *
BAE SEON HEE ET AL: "Platelet activation in patients with diabetic retinopathy.", KOREAN JOURNAL OF OPHTHALMOLOGY : KJO DEC 2003, vol. 17, no. 2, December 2003 (2003-12-01), pages 140 - 144, XP002470690, ISSN: 1011-8942 *
CHAPMAN E SABRINAH ET AL: "A rapid, automated flow cytometric method to measure activated degranulated platelets by density determination.", THROMBOSIS AND HAEMOSTASIS, vol. 89, no. 6, June 2003 (2003-06-01), pages 1004 - 1015, XP002470691, ISSN: 0340-6245 *
MO VIVIAN Y ET AL: "Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy.", CURRENT CARDIOLOGY REPORTS JUL 2004 LNKD- PUBMED:15182604, vol. 6, no. 4, July 2004 (2004-07-01), pages 273 - 278, XP009133464, ISSN: 1523-3782 *
See also references of WO2006014958A2 *
WU ALAN H B: "Markers for early detection of cardiac diseases.", SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION. SUPPLEMENTUM 2005 LNKD- PUBMED:16112968, vol. 240, 2005, pages 112 - 121, XP008062995, ISSN: 0085-591X *

Also Published As

Publication number Publication date
US20100173339A1 (en) 2010-07-08
WO2006014958A2 (en) 2006-02-09
US7723064B2 (en) 2010-05-25
US20080311606A1 (en) 2008-12-18
WO2006014958A3 (en) 2006-06-22
EP1814563A2 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
HK1171736A1 (en) Substituted acids for the treatment of respiratory diseases
IL164799A0 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
IL212985A0 (en) Therapeutic uses of inhibitors of rtp801
HK1089107A1 (en) Delivery of therapeutic compounds to the brain and other tissues
PL1673104T3 (en) Delivery of therapeutic compounds to the brain and other tissues
EP1638605A4 (en) Delivery of therapeutic compounds to the brain and other tissues
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
IL183781A0 (en) Pyridine compounds for the treatment of prostaglandin mediated diseases
EP1789027A4 (en) Therapeutic use of anti-tf-antigen antibody
GB0305150D0 (en) Use of therapeutic compounds
IL177752A0 (en) Ester derivatives of rhein and their therapeutic use
EP1814563A4 (en) Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress
EP2175722A4 (en) Patient selection and therapeutic methods using markers of prostaglandin metabolism
EP1740541A4 (en) Therapeutic formulations of desoxyepothilones
IL178970A0 (en) Haplotype markers and methods of using the same to determine response to treatment
EP1773882A4 (en) Diagnosis and treatment of siglec-6 associated diseases
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
EP1827458A4 (en) Selective inhibition of rock 1 in cardiac therapy
IL175674A0 (en) Method to improve the efficacy of therapeutic radiolabeled drugs
IL178120A0 (en) Therapeutic combination for treatment of alzheimers disease
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases
EP1846013A4 (en) Treatment of skin diseases
ZA200606780B (en) Compounds for the treatment of diseases
IL172061A0 (en) Further therapeutic use of zolpidem
AP2007004017A0 (en) Pyridine compounds for the treatment of prostaglandin mediated diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070226

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080313

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIEMENS HEALTHCARE DIAGNOSTICS INC.

17Q First examination report despatched

Effective date: 20080707

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130522

18W Application withdrawn

Effective date: 20130522